Skip to content

Welcome to Discover Pharma! Today is : November 22, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

phase 3 trial

  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics

    AstraZeneca’s Imfinzi recommended by NICE for resectable gastric and gastro-oesophageal junction cancer

    AstraZeneca’s Imfinzi (durvalumab) has been recommended by NICE for use [...]

    May 14, 2026
  • Advanced Therapies,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Intellia reports first positive Phase 3 in vivo CRISPR data in hereditary angioedema

    Intellia Therapeutics has reported positive Phase 3 results for lonvoguran [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    Efzimfotase alfa shows mixed Phase 3 results in hypophosphatasia across pediatric and adult patients

    Efzimfotase alfa has shown positive Phase 3 results in children [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    PolyPid prepares D-PLEX100 NDA following Phase 3 surgical infection data

    PolyPid is preparing to submit a New Drug Application for [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Delivery & Formulation,Pharmaceuticals and therapeutics,Therapeutic Areas

    Exdensur approved by European Commission for severe asthma and chronic rhinosinusitis with nasal polyps

    GSK announced that the European Commission has approved Exdensur (depemokimab) [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    ViiV Healthcare highlights ultra long-acting HIV pipeline and Phase 1 data at CROI 2026

    ViiV Healthcare will present new data from its long-acting and [...]

    May 5, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Compass Pathways reports positive second Phase 3 trial for COMP360 in treatment-resistant depression

    Compass Pathways has reported that its second pivotal Phase 3 [...]

    May 5, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Boehringer Ingelheim’s apecotrep reduces proteinuria in Phase 2 FSGS trial

    Boehringer Ingelheim has reported Phase 2 clinical trial results showing [...]

    May 5, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Scancell clears FDA IND for iSCIB1+ registrational Phase 3 trial in advanced melanoma

    Scancell Holdings has announced that the U.S. Food and Drug [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Bicara announces Phase 3 optimal dose for ficerafusp alfa and provides 2026 corporate outlook

    Bicara Therapeutics has selected 1500 mg of ficerafusp alfa as [...]

    May 5, 2026
Previous123Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Skylark Bio advances hearing loss gene therapy to younger children
    Categories: Advanced Therapies
  • Fonseca reports Phase 3 success for new swimmer’s ear treatment
    Categories: Clinical & Regulatory
  • Almirall wins positive CHMP opinion to expand Klisyri treatment area for actinic keratosis
    Categories: Pharmaceuticals and therapeutics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top